MentionFox
Home › Executive changes › Arcadia Biosciences, Inc.
Leadership changes · RKDA · SEC Form 8-K, Item 5.02

Leadership changes at Arcadia Biosciences, Inc. (2026)

Before you join, sell to or invest in Arcadia Biosciences, Inc.

MentionFox check on Arcadia Biosciences, Inc.: no red flags found in 3 sources; 1 item to note (checked 14 November 2026). mentionfox.com/c/executive-changes/arcadia-biosciences

  • Note: Patent, trademark or copyright suit filed Apr 2019 (court record)

Check Arcadia Biosciences, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Arcadia Biosciences, Inc.?

Who joined and who left Arcadia Biosciences, Inc. (RKDA)? 2 filings reported from 2026-02-06 to 2026-07-02, each cited to the company's own filing.

As of November 14, 2026, Arcadia Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 6, 2026 to July 2, 2026 (Form 8-K, July 2, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

MJL Manager LLC also filed stake reports on 3 other companies ↓

Sell to companies like Arcadia Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
Latest filing2026-07-02

Arcadia Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-06 to 2026-07-02. Every row below is cited to the filing it comes from, and this page adds each new change as Arcadia Biosciences, Inc. files it.

Also on the record for Arcadia Biosciences, Inc.

DateRecordFigureOur pageSource
September 30, 2026Stake report, Schedule 13G, by MJL Manager LLC15.7% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Armistice Capital, LLC9.99% of the class5%+ stakesSource
June 26, 2026Form D, private offering$4M soldForm D pageSource
May 15, 2026Stake report, Schedule 13G, by Armistice Capital, LLC7.75% of the class5%+ stakesSource
January 27, 2026Form D, private offering$2.08M soldForm D pageSource
April 1, 2019Court case: Bay State Milling Company v. Arcadia Biosciences, Inc., District Court, D. Delaware—Court recordsSource

Selling to them or working with them? See who runs Arcadia Biosciences, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Arcadia Biosciences, Inc. and the records around it.

Arcadia Biosciences, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Arcadia Biosciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Arcadia Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Arcadia Biosciences, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-07-02Reportednot named in the filing8-K, 2026-07-02
2026-02-06Reportednot named in the filing8-K, 2026-02-06
Selling to Arcadia Biosciences, Inc.?

New leaders reset buying decisions — get the Full Report on Arcadia Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Arcadia Biosciences, Inc. (free up to 3)

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Arcadia Biosciences, Inc., with the record behind each one.

Find candidates like senior executive at Arcadia Biosciences, Inc.

Every change, in the filing's words

Filed 2026-07-02 · 8-K

Reported

Mr. Kawakami resigned as an officer and employee effective September 12, 2025, and his options have expired and terminated.

Also stated in this filing

  • On April 30, 2026, Arcadia Biosciences, Inc. (the "Company") filed an amendment to its Annual Report on Form 10-K/A (the "Form 10-K/A") with the Securities and Exchange Commission (the "Commission").
  • Instead, the amounts represent aggregate grant date fair value of options granted during 2025 computed in accordance with ASC Topic 718 Stock Compensation.
  • The valuation assumptions used in determining such amounts are consistent with those described in Note 13 of the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.
  • On May 9, 2025, each of Mr. Schaefer and Mr. Kawakami was granted an option to purchase 12,500 shares of common stock under our 2015 Omnibus Equity Incentive Plan.
  • The stock options have a term of ten years and vest over four years, with 25% of the shares subject to the stock options vesting on the first anniversary of the grant date, and an additional 1/36th of the shares vesting each month thereafter, subject to continued service through the applicable vesting dates.
  • (2) The amounts shown for 2024 represent amounts earned pursuant to our Executive Incentive Bonus Plan for services in 2024, which were paid in 2025.
  • The amounts for 2024 were determined based on a weighting of the achievement of Financial and Individual Goals.
Filed 2026-02-06 · 8-K

Reported

Their resignation was not because of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, practices or financial statements.

Also stated in this filing

  • (b) Resignation of Directors On February 4, 2026, each of Albert D. Bolles, Ph.D., a director and member of the Compensation Committee of the board of directors (the "Board") of Arcadia Biosciences, Inc. (the "Company"), and Deborah Carosella, a director and member of the Compensation Committee and Nominating and Governance Committee of the Board, notified the Company that effective as of February 4, 2026, such person was resigning as a director of the Company and all subsidiaries of the Company of which such person was a director.
  • Each person agreed to be available to provide assistance as an advisor.

Tools for this story

Each opens in a new tab, filled in for Arcadia Biosciences, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/arcadia-biosciences
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Arcadia Biosciences, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/arcadia-biosciences